NCT00512343 Synovial Fluid Bank From Arthritic Patients
| NCT ID | NCT00512343 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Gilles Boire |
| Condition | Arthritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2002-06 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2002-06 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objectives of this group project is to collect synovial fluid (SF) and paired sera and carry out preclinical studies to evaluate, alone or by combination testings, the potential of novel biomarkers for their prevalence and diagnostic/prognostic values in patients with arthritis, and to determine how therapeutic intervention regulate their levels.
Eligibility Criteria
Inclusion Criteria: * Significant joint effusion Exclusion Criteria: * Hemorrhagic effusion * Traumatic effusion * Less than 3 ml total of collected fluid (used for routine analysis and culture) * Inability or refusal to consent
Contact & Investigator
Gilles Boire, MD, MSc
PRINCIPAL INVESTIGATOR
CHUS and Université de Sherbrooke
Frequently Asked Questions
Who can join the NCT00512343 clinical trial?
This trial is open to participants of all sexes, aged 3 Years or older, up to 95 Years, studying Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00512343 currently recruiting?
Yes, NCT00512343 is actively recruiting participants. Contact the research team at Gilles.Boire@USherbrooke.ca for enrollment information.
Where is the NCT00512343 trial being conducted?
This trial is being conducted at Sherbrooke, Canada.
Who is sponsoring the NCT00512343 clinical trial?
NCT00512343 is sponsored by Gilles Boire. The principal investigator is Gilles Boire, MD, MSc at CHUS and Université de Sherbrooke. The trial plans to enroll 500 participants.